Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Bulman Lab

Zackery Bulman

Dr. Bulman is an Assistant Professor in the Department of Pharmacy Practice at the University of Illinois Chicago and runs the Precision Antimicrobial Laboratory. His group aims to devise novel therapeutic approaches that are capable of successfully treating infectious diseases while also suppressing the amplification of new resistance mechanisms. His laboratory is developing cutting-edge pharmacokinetic and pharmacodynamic treatment approaches for antibiotics to help combat multidrug-resistant bacteria. Implementing clinical pharmacokinetic data from patients, Dr. Bulman’s lab simulates the human exposures of antimicrobials in the laboratory to evaluate their pharmacodynamic effects.

Ongoing work aims to repurpose and revitalize older antibiotics for bacteria with emerging resistance mechanisms in preparation for continued clinical outbreaks of carbapenem-resistant Gram-negatives. Dr. Bulman is currently leading a project that is exploring combinations between aminoglycosides and β-lactam/β-lactamase inhibitors for these highly resistant pathogens (2022-2027, R01AI173064). The Precision Antimicrobial Laboratory also seeks to develop models that can predict phenotypic resistance based on bacterial genotype. Dr. Bulman is also interested in optimizing treatment of biofilms and the use of inhaled antibiotics for patients with pneumonia.

Lab Highlights Heading link

Recent updates from the Bulman Lab.

Dr. Bulman Leads Team to Highlight Key PK/PD Research Priorities Heading link

Dr. Bulman, in collaboration with leaders from 3 international infectious disease societies, led the development of a personal view article published in Lancet Microbe that sought to emphasize several key research priorities in antibiotic PK/PD. Although progress has been made in our quest to optimize the treatment of infections, additional research will be required to fully realize the potential of precision antibiotic therapy and its ability to improve patient outcomes. The article was also featured on ContagionLive.

Bulman et al. Lancet Microbe

Dr. Bulman Receives $3.66M R01- Among Largest R01's in the History of the UIC College of Pharmacy Heading link

Dr. Zackery Bulman recently received a $3.66 million, 5-year R01 grant as PI for his project titled, “Precise Combination Strategies Targeting Carbapenem-Resistant Klebsiella pneumoniae” (R01AI173064). This R01 is the largest R01 in the history of the UIC College of Pharmacy (based on NIH Reporter data). This project will develop new antibiotic combination treatment approaches for drug-resistant superbugs, which can cause serious infections associated with high mortality rates.

Press Release

@PrecisionAbxLab Heading link